Shares of Baxter International (BAX) Sees Large Inflow of Net Money Flow

Baxter International (BAX) : Baxter International (BAX) had a healthy money flow of $1.07 million into the stock during the Fridays trading session. The value of bullish trades on upticks was $6.33 million, whereas, investors only sold shares worth $5.26 million on downticks. The stock closed the day with an up-down ratio of 1.2.The money flow in the block trades to the tune of $2.12 million shows that the bulls were dominant, the large players used the weakness in the stock to accumulate it for the long-term. $2.12 million worth of transactions were on upticks. Baxter International (BAX) stock slid $0.06 intraday and traded at 46.12, a change of -0.13% over previous days close. However, for the week, the company shares are -2.25% compared to previous weeks close.


The company Insiders own 1.08% of Baxter International shares according to the proxy statements. Institutional Investors own 85.74% of Baxter International shares.

In a related news, Almeida Jose E, CEO of Baxter International Inc, had purchased 11,691 shares on May 23, 2016. The total value of the transaction was $499,790. The information was disclosed with the SEC in a Form 4 Filing. The information is based on open market trades at the market prices.Option exercises are not covered.

Baxter International (NYSE:BAX): The stock opened at $46.38 and touched an intraday high of $46.44 on Friday. During the day, the stock corrected to an intraday low of $46.08, however, the bulls stepped in and pushed the price higher to close in the green at $46.28 with a gain of 0.22% for the day. The total traded volume for the day was 3,081,365. The stock had closed at $46.18 in the previous trading session.

Baxter International (BAX) : During the past 4 weeks, traders have been relatively bearish on Baxter International (BAX), hence the stock is down -3.58% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -2.4% relative to the S&P 500. The 4-week change in the price of the stock is -3.7% and the stock has fallen -1.91% in the past 1 week.

Baxter International Inc. (Baxter) is a diversified healthcare company. The Company operates in two segments: BioScience segment, which include three commercial franchises: Hemophilia, BioTherapeutics and BioSurgery, and Medical Products segment, which include four commercial franchises: Fluid Systems, Renal, Specialty Pharmaceuticals and BioPharma Solutions. Its BioScience processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions, and biosurgery products. Its Medical Products manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps and inhalation anesthetics. Its products are used in hospitals, kidney dialysis centers and nursing homes, among others.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.